about
Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis.Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) geneDevelopment of delivery methods for carbohydrate-based drugs: controlled release of biologically-active short chain fatty acid-hexosamine analogsPolysaccharide A from the capsule of Bacteroides fragilis induces clonal CD4+ T cell expansion.Bacterial capsular polysaccharide prevents the onset of asthma through T-cell activation.Glycosylation changes as markers for the diagnosis and treatment of human disease.The regulatory power of glycans and their binding partners in immunityB-cell-independent sialylation of IgG.Dendritic cell-specific Mgat2 knockout mice show antigen presentation defects but reveal an unexpected CD11c expression pattern.T cell-intrinsic TLR2 stimulation promotes IL-10 expression and suppressive activity by CD45RbHi T cells.Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells.Polysaccharide-experienced effector T cells induce IL-10 in FoxP3+ regulatory T cells to prevent pulmonary inflammation.Metabolic expression of thiol-derivatized sialic acids on the cell surface and their quantitative estimation by flow cytometry.Plasma glycomics predict cardiovascular disease in patients with ART-controlled HIV infectionsCD45Rb-low effector T cells require IL-4 to induce IL-10 in FoxP3 Tregs and to protect mice from inflammation.IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acidsCosmc is required for T cell persistence in the periphery
P50
Q34042797-2714BEC2-CBCB-4B4A-9B71-7DAB3E431300Q34199547-56A2C37A-3300-499E-A2A0-A18789EDE484Q34573505-B1DDF31D-7140-4A51-A9DF-37C29E6A8449Q35103983-A605159F-E06A-4DD1-9897-89D9D26DA99BQ35119767-C381B531-25A0-42F9-8690-D590C936308EQ35681016-ABA0229B-D716-4C91-8DF7-AB1713CBA627Q36906422-D0C78729-E301-4740-B8EE-9F5B9641FFD7Q37065114-4CC3FF09-8D24-48EC-832B-D19CDB394F1FQ39794153-2A4FFE0D-ACC5-46B0-B9E4-F19F6AE10C24Q41939919-F6581D63-369F-4B38-AD06-32F048D7F1F6Q44765733-2D924B31-DFA7-40A2-A721-44CD725CCA43Q47993658-43CA20C4-4D13-46E5-95C7-5B10F2E42E2BQ51009449-C5D2109B-BB91-4F6D-BB3A-66E368CD3D15Q57160588-D9308671-F258-49F9-B13D-6E213DF8CFC5Q64996802-7B344977-080A-4B73-B4FE-2D16ED3A815EQ88445153-EBB59193-9210-4503-A444-A9FBAA25BEAEQ91977042-353D4F94-6938-4784-8B06-6AA5DF90C896
P50
description
researcher
@en
name
Mark B Jones
@en
Mark B Jones
@nl
type
label
Mark B Jones
@en
Mark B Jones
@nl
prefLabel
Mark B Jones
@en
Mark B Jones
@nl
P106
P31
P496
0000-0002-8685-4001